Proprietary targeted immunotherapy technology personalized to match unmet needs of advanced breast cancer patients Ongoing clinical studies of lead candidate, Bria-IMT, continue to show robust biological activity, excellent safety profile Breast cancer is one of the most commonly diagnosed cancers, with 2.1 million new cases expected in 2018 Global cancer immunotherapy market is projected to … Continue reading “BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Receives Equity Investment to Support Novel Immunotherapy Clinical Research”
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, this morning announced a non-brokered private placement financing of 5,000,000 of its common shares, each at a price of C$0.10, for gross proceeds of C$500,000. According to the update, recently-appointed BriaCell Director Jamieson Bondarenko will purchase the 5,000,000 common shares … Continue reading “NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Director to Invest C$500,000 in Private Placement Financing”
BriaCell Therapeutics Corp. will reveal important information about Bria-IMT and Bria-OTS at two leading conferences – the ASCO-SITC Clinical Immuno-Oncology Symposium and the American Association of Cancer Research’s annual meeting New information will also be made available about the company’s HLA-identification test, BriaDX, which is aimed at identifying patients most likely to benefit from Bria-IMT … Continue reading “BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Announce Breast Cancer Immunotherapy Findings at Key Oncology Conferences”
Developing Bria-OTS, the first off-the-shelf personalized immunotherapy for advanced breast cancer Initiated FDA-approved phase IIa combination study of BRIA-IMT with Merck & Co. Inc.’s KEYTRUDA Impressive results in two proof-of-concept clinical trials reveal rapid response rate, repeated response following retreatment and excellent safety profile Cancer immunotherapy market is anticipated to grow to $145 billion by … Continue reading “BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Targets Advanced Breast Cancer with Proprietary Immunotherapy”
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, today announced that it will present clinical and scientific findings at key oncology conferences. According to the update, the company was selected to present a poster at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, to be held in San Francisco, California … Continue reading “NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) to Present Clinical and Scientific Findings at Key Oncology Conferences”
On February 12, 2019 Jamieson Bondarenko, a recently appointed member of BriaCell Therapeutics’ (OTCQB: BCTXF) (TSX.V: BCT) Board of Directors, acquired 2,000,000 common shares of the company through the facilities of the TSX Venture Exchange at a price of $0.0975 per share for a total purchase price of $195,000. Bondarenko previously held 16,070,500 common shares … Continue reading “NetworkNewsBreaks – Newly Appointed Board of Directors Member Increases Beneficial Ownership of BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT)”
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, this morning announced the appointment of Jamieson Bondarenko, CFA, CMT, to the company’s Board of Directors. Through his merchant capital company, JGRNT Capital Corp., Bondarenko currently offers strategic capital markets and corporate development advice to early-stage life sciences … Continue reading “NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Appoints New Member to Board of Directors”
Multiple breakthroughs in the field of onco-immunology are expected over the next 20 years BriaCell Therapeutics Corp. is a frontrunner in this area, as it has already established proof of concept for its Bria-IMT solution for advanced breast cancer patients The company is also developing Bria-OTS, a personalized off-the-shelf solution, that will be much easier … Continue reading “Immunotherapy is the ‘Next Era’ of Cancer Treatment and BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is Taking Steps Forward in this Field”
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, is currently developing immunotherapy solutions demonstrated to be highly effective and well tolerated by patients. The market share for immunotherapy treatments for breast cancer as well as other malignancies is forecasted to surge in the coming years. An article discussing the company reads, … Continue reading “NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Developing Novel Treatment Options for Cancer Patients in Booming Market Forecasted to Reach $145 Billion by 2022”
BriaCell Therapeutics (OTCQB: BCTXF) (TSX.V: BCT), a biotechnology company focused on immuno-oncology, is advancing the development of a cost-saving solution for cancer patients. An article discussing the company reads, “BriaCell’s development of Bria-OTS, a personalized immunotherapy solution that matches the needs of the patient without a specialized manufacturing process, is designed to mitigate some of … Continue reading “NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advances Development of Personalized Immunotherapy Solution for Cancer Patients”
